|
National Institutes of Health (“NIH”) presents Chronocort® Phase 2 clinical trial results at ENDO in San Francisco
17 June 2008 05:40 pm
West Malling, UK, 17 June 2008: Phoqus Pharmaceuticals plc (AIM: PQS) (“Phoqus” or the “Company”), the speciality pharmaceutical company, announces that the results of the Phase 2 clinical trial of Chronocort #004 were presented on 15 June by the NIH at the Endocrine Society meeting in San Francisco.
As announced by Phoqus on 3 March 2008, the conclusions from the study are that Chronocort® is safe and well tolerated in patients with Congenital Adrenal Hyperplasia (“CAH”), with Chronocort® providing a more physiological cortisol profile than conventional therapy. A single daily dose of Chronocort® given at 10pm provided a physiological night time and morning cortisol profile and control of morning levels of the androgens ACTH and 17-OHP in patients with CAH. Whilst dose optimisation has not yet been studied, it is likely that giving the daily dose of Chronocort® in two divided doses will improve androgen levels throughout the whole 24 hour period. A study to evaluate Chronocort® given twice daily to patients with CAH is being planned with the NIH prior to initiation of a multi-centre trial.
Phoqus Pharmaceuticals’ CEO, Dr Richard Mason, commented:
“These results give us great confidence that Chronocort is working as expected and that it will be a major step forward in the treatment of Congenital Adrenal Hyperplasia and other forms of adrenal insufficiency including Addison's disease. Partnering discussions are proceeding well with a number of speciality pharmaceutical and biotechnology companies.”
Source: http://www.phoqus.com
|
